Objective-To examine the relationship of plasma levels of matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinase 1 (TIMP-1) with carotid artery characteristics measured by MRI in a cross-sectional investigation among Atherosclerosis Risk in Communities Carotid MRI Study participants. Methods and Results-A stratified random sample was recruited based on intima-media thickness from a previous ultrasonographic examination. A high-resolution gadolinium-enhanced MRI examination of the carotid artery was performed from 2004 to 2005 on 1901 Atherosclerosis Risk in Communities cohort participants. Multiple carotid wall characteristics, including wall thickness, lumen area, calcium area, lipid core, and fibrous cap measures, were evaluated for associations with plasma MMPs 1, 2, 3, 7, 8, and 9 and TIMP-1. Plasma MMPs 1, 3, and 7 were significantly higher among participants in the high intima-media thickness group compared with those in the low intima-media thickness group. The normalized wall index was independently associated with MMPs 3 and 7 and TIMP-1. MMP-7 was positively associated with carotid calcification. The mean fibrous cap thickness was significantly higher in individuals with elevated TIMP-1 levels. In addition, TIMP-1 was positively associated with measures of lipid core. Conclusion-Circulating levels of specific MMPs and TIMP-1 were associated with carotid wall remodeling and structural changes related to plaque burden in elderly participants. (Arterioscler Thromb Vasc Biol. 2010;30:1034-1042.) 
A therosclerosis, the major cause of cardiovascular disease (CVD) and stroke, is a complex inflammatory process that is characterized by the formation of raised arterial lesions, eventually resulting in the narrowing of the lumen. 1 Of the individuals who experience an adverse cardiovascular event, up to 50% have no apparent established traditional risk factor present. 2 Recent studies suggest that matrix metalloproteinases (MMPs) play an important role in the early vascular remodeling that accompanies the progression from the initial intima-media thickness (IMT) to the development of a large atheromatous plaque and ultimately to the erosion of the extracellular matrix of the fibrous cap, which contributes to plaque destabilization and rupture. 3 The MMP family consists of more than 24 members of zinc endopeptidases, which target a wide variety of substrates, including most of the extracellular matrix components that compose the arterial wall. 4 MMPs 1 and 8 are interstitial collagenases with the ability to cleave the major fibrillar collagens. MMPs 2 and 9 are gelatinases that have the ability to digest vascular smooth muscle cell (SMC) basement membranes, collagen, and elastin. MMP-3 is a stromelysin that can degrade a wide variety of substrates, including proteoglycans, collagen, and decorin. MMP-7, which belongs to the matrilysins, has a broad range of substrates, including collagen and laminin. MMPs are secreted by a variety of cells, such as endothelial cells, vascular SMCs, and cells involved in the inflammatory cascade. 5 The proteolytic activities of MMPs are tightly regulated; a variety of endogenous inhibitors, including tissue inhibitor of metalloproteinase (TIMP), are involved. 4 TIMP-1, the first discovered and most widely studied of the TIMPs, inhibits most of the active MMPs.
Systemic MMP or TIMP levels may constitute markers of the atherosclerotic process, occurring in the vascular tree, that are independent of traditional risk factors. 6 Adenovirusmediated overexpression of TIMP-1 in atherosclerosissusceptible apolipoprotein E-deficient mice significantly reduced atherosclerotic lesions. 7 In 1 of the few direct studies of human arterial tissue, MMPs 2 and 9 and TIMPs 1 and 2 were localized and quantified in carotid endarterectomy tissues of healthy and atherosclerotic regions. 8 The abundance of both MMPs was greater in plaque than in healthy segments. TIMPs were less abundant in calcified regions and more abundant in fibrotic and necrotic segments. In a study 9 using both human autopsy and surgical specimens, increased expression of MMP-1 was found in vulnerable atherosclerotic plaques compared with nonlesion areas of the vessel. In a small study 10 of 33 patients, peripheral blood levels of MMPs 2 and 9 were increased in patients with acute coronary syndrome. In a recent case-control study 11 of premature coronary disease in 53 consecutive male patients, plasma levels of MMPs 2, 3, and 9 and TIMPs 1 and 2 were measured; significant differences were found in all MMPs and TIMPs between patients and control subjects.
Although several epidemiological studies have used carotid ultrasonography to measure carotid IMT and assess the presence or absence of plaque, carotid ultrasonography, as performed in the Atherosclerosis Risk in Communities (ARIC) and other studies, cannot reliably quantify plaque and wall volumes, lumen area, or vascular remodeling. MRI can extend the basic ultrasonographic measurements to assess plaque burden and vascular remodeling. For example, MRIderived variables, such as the "normalized wall index" (NWI), can provide a measure of plaque burden that accounts for inherent differences in wall area among vessels of differing diameters. In addition, MRI provides the opportunity to measure, albeit with less accuracy, other structural components, such as the fibrous cap, the lipid core, and calcification.
To our knowledge, there are no comprehensive studies that have explored the relationships between multiple MMPs and TIMP-1 and specific parameters of carotid artery wall architecture, as measured by MRI. Therefore, we have investigated the association of circulating levels of MMPs and TIMP-1 with carotid artery wall characteristics in the large biracial ARIC Carotid MRI Study cohort.
Methods

Study Design and Participants
The ARIC Study is a prospective investigation of atherosclerosis involving 15 792 black and white men and women aged 45 to 64 years at recruitment (1987) (1988) (1989) . Participants underwent a baseline and up to 3 follow-up visits through 1998. A detailed description of the ARIC study design and methods has been published elsewhere. 12 The ARIC Carotid MRI Study was conducted between 2004 and 2005 as a cross-sectional substudy. The participants were selected from the larger ARIC study cohort based on the results of the last ultrasonographic examinations (visits 3 and 4, 1993 to 1998). To increase the prevalence of informative plaques while maintaining the ability to make population-based inferences, a stratified sampling plan was used. The goal was to recruit 1200 participants with high values of maximum carotid artery wall thickness (maximum over 6 sites: common, bifurcation, and internal carotid arteries of the left and right sides) and 800 participants randomly sampled from the remainder of the cohort below this threshold. This carotid artery IMT threshold was determined for each field center based on the IMT distribution specific to that site, and field center-specific threshold of carotid IMT were adjusted over the recruitment period to approximately achieve this goal.
Recruitment lists were provided to the field centers, which sampled from above and below the IMT threshold, as indicated by the sampling plan. Ineligibility criteria for the ARIC Carotid MRI Study included standard contraindications to the MRI examination findings or to the contrast agent, carotid revascularization on either side for the low IMT group, or carotid revascularization on the imaging-selected side for the high IMT group. Of the total 4307 persons who were contacted and invited to participate in the study, 1404 refused, 837 were ineligible, and 2066 participated. The overall recruitment rates were 40%, 48%, 51%, and 53% of all persons contacted from the 4 centers, with little difference in rates between the high and low IMT groups. In addition, selected participants also answered questions during in-person interviews and underwent a physical examination.
Of these 2066 ARIC cohort members who participated in the ARIC Carotid MRI Study, 1901 underwent a complete MRI examination. Of these 1901 participants, 1769 had sufficient-quality MRI scans, with adherence to the MRI protocol. In addition, 91 participants with 1 or more missing values for any of the MMP or TIMP-1 measurements were excluded, leaving 1678 subjects in the final analyses. The average age of these 1678 participants was 70 years, including 1304 whites (632 women and 672 men) and 374 blacks (220 women and 154 men).
Participant Examination Findings
Protocols for lipoprotein and fasting glucose levels and blood pressure (BP) and height and weight measurements were identical at the ARIC cohort baseline examination and the ARIC Carotid MRI Study examination conducted 18 years later. Cigarette smoking was ascertained from an interview and categorized as "current," "former," or "never." Prescription drug use was obtained by selfreport. Fasting blood samples were collected and assayed for total cholesterol and high-density lipoprotein cholesterol levels. Lowdensity lipoprotein cholesterol was calculated according to the Friedewald formula. We assessed C-reactive protein (CRP) levels by an immunoturbidimetric high-sensitivity assay (CRP-Latex [II]; Denka Seiken, Tokyo, Japan), performed according to the manufacturer's protocol using an automated chemistry analyzer (Olympus AU400e; Olympus America Inc, Melville, NY). Resting BP was determined 3 times using a random-zero sphygmomanometer, and the mean of the last 2 measurements was used. Hypertension was defined as a systolic BP of 140 mm Hg or higher, a diastolic BP of 90 mm Hg or higher, or use of antihypertensive medication during the previous 2 weeks. Diabetes mellitus (DM) was defined as a fasting glucose level of at least 126 mg/dL, a nonfasting glucose level of at least 200 mg/dL, or a self-reported history of physiciandiagnosed DM or treatment for DM. A previous history of CVD included an adjudicated myocardial infarction, coronary heart disease-related death, stroke, and/or a revascularization procedure. 13 The present study was approved by the institutional review committees of all participating centers; all participants provided informed consent.
MRI Protocol
MRI studies were performed on a 1.5T scanner (GE Medical Systems, Milwaukee, Wis at 3 field centers; and Siemens Medical Solutions, Ehrlangen, Germany at 1 field center) equipped with a bilateral 4-element phased array carotid coil (Machnet, The Netherlands). A 3-dimensional time-of-flight magnetic resonance angiogram was acquired through both carotid bifurcations. Detailed black blood MRI images were then acquired through the extracranial carotid bifurcation known to have a thicker maximum wall by the most recent ultrasonographic study, unless the technologist determined that the contralateral carotid bifurcation wall appeared thicker on the magnetic resonance angiogram. Black blood MRI was achieved using a cardiac-gated, 2-dimensional, double-inversion recovery fast spin-echo sequence, with the inversion time set to suppress the signal of blood. Each participant received an intravenous injection of gadodiamide (Omniscan, GE Amersham, Buckinghamshire, England), 0.1 mmol/kg body weight, using a power injector. Sixteen transverse T1-weighted black blood MRI images (acquired resolution, 0.51ϫ0.58ϫ2.00 mm 3 ; total longitudinal coverage, 3.2 cm) were oriented perpendicular to the vessel and centered at the thickest part of the internal or common carotid artery wall. These 16 slices were acquired 5 minutes after the injection through the thicker carotid artery using a 2-dimensional double-inversion recovery fast spin-echo sequence, with the inversion time set to suppress the signal of the contrast-enhanced blood pool.
Image Analysis
The MRIs were analyzed by 7 specially trained readers, blinded to the clinical and laboratory characteristics of the study population. All examinations were assessed for image quality and protocol adherence; examinations that failed to follow these protocols were not analyzed.
Slices were numbered 1 through 16 from proximal to distal; only 8 slices, centered around the slice with the thickest wall, were analyzed. The plaque components were analyzed on the postcontrast black blood MRI series based on the ability of gadolinium enhancement to delineate and enable quantitative size measurements of the fibrous cap 14 ; contours were drawn to delineate the outer wall, the lumen, the lipid core, and calcification. The total vessel area included the lumen, the intima, the media, and the adventitia. Wall area was calculated as the difference between total vessel area and lumen area. The derived MRI variable, NWI, was calculated by dividing the wall area by the total vessel area. Reliability coefficients (R) for the previously mentioned MRI variables were obtained from an internal reliability study; these data have been published previously. 15 Generally, the reliability for most MRI variables varied from excellent (RϾ0.75) to fair to good (0.40ϽRϽ0.75). However, the limited resolution of the 1.5-T MRI scanner may have contributed to the lower reliability of measurements related to relatively small structural features, such as the fibrous cap thickness. Although reliability based on repeated readings was fair to good for cap thickness measures (Rϭ0.60), reliability based on repeated scans was poor for cap thickness (Rϭ0.38). A detailed description of the image analysis methods for the ARIC Carotid MRI Study was published previously. 15
Multianalyte Profiling Assay
A fluorokine multianalyte profiling (MAP) assay allows the simultaneous measurement of multiple biomarkers from small sample volumes. In the current study, 6 MMP analytes were measured using an assay from R&D Systems, Inc, Minneapolis, Minn, according to the manufacturer's protocol, with the following minor modifications. Because of differences in the plasma levels of the MMPs and the sensitivity of the assay, 2 dilutions were used. Panel A measured MMPs 1, 7, and 8, which required a 2-fold dilution; panel B measured MMPs 2, 3, and 9, which required a 10-fold dilution. MMP control materials were obtained from R&D Systems, Inc, Minneapolis, Minn; and appropriate mixtures for panels A and B were run for each assay. Duplicates were run for all test samples, controls, and standards. Software (Bio-Plex Manager 4.1; BioRad Labs, Hercules, Calif) was used for data acquisition. TIMP-1 was measured with a solid-phase sandwich ELISA technique (R&D Systems, Inc), according to the manufacturer's protocol. Reliability coefficients for MMPs 1, 2, 3, 7, 8, and 9 and TIMP-1 were as follows: 0.87, 0.61, 0.66, 0.82, 0.79, 0.78, and 0.60, respectively. These coefficients were based on blinded replicate pairs of 60 participants. The intra-assay coefficients of variation for MMPs 1, 2, 3, 7, 8, 9, and TIMP-1 were as follows: 7.0%, 3.4%, 3.9%, 5.1%, 7.6%, 3.6%, and 4.7%, respectively. The interassay coefficients of variation for MMPs 1, 2, 3, 7, 8, 9, and TIMP-1 were as follows: 8.6%, 5.9%, 6.2%, 12.6%, 11.5%, 5.6%, and 6.9%, respectively. The MMPs were measured as the total of all forms, including pro-, mature-, and TIMP-complexed forms; total TIMP-1 was also measured as both the free-and MMP-complexed forms.
Statistical Analysis
All analyses were based on methods appropriate for a stratified random sampling. In particular, all analyses were weighted by the inverse of the sampling fractions in the 8 sampling strata (4 field centersϫ2 IMT groups). The sampling fractions were based on those persons screened for participation. Those who actually participated were analyzed as a domain for calculating variances and CIs of estimators. Analyses were conducted using computer software for descriptive statistics (SAS, version 9.1; SAS Institute Inc, Cary, NC) or for domain analysis (SUDAAN; RTI International, The Research Triangle, NC). Finite population correction factors were not applied. Tests of differences in weighted means or proportions between groups were from weighted linear or logistic regression models that accounted for the sampling. Adjusted means and proportions by sub-group of interest were calculated using the SUDAAN REGRESSION procedure for continuous variables and the LOGISTIC procedure for dichotomous variables, with predicted values calculated as sample means of the adjusting variables. Wall thickness and wall volume were analyzed in the full data set of 1678 participants. Because of the resolution constraints of the MRI scan, we restricted consideration of lipid core to the 1156 participants whose maximum wall thickness was 1.5 mm or greater (weighted percentage, 62%). Only 4 lipid cores were excluded using this threshold. Measures of lipid core volume and area and fibrous cap thickness were analyzed as continuous variables among those 554 participants with a lipid core. An additional analysis considered correlates of lipid core presence as a dichotomous variable. Standardized regression coefficients are presented for linear and logistic regression models, standardizing by 1 SD of exposure and outcome (for continuous outcomes), with adjustment for age, race, and sex.
Results
We investigated the relationship between circulating levels of MMPs and TIMP-1 and several traditional cardiovascular risk factors, as shown in Table 1 . With the exception of MMP-9, all measured MMPs and TIMP-1 were positively associated with age. Interestingly, MMPs 1 and 2 were negatively associated with low-density lipoprotein cholesterol level. We also found that circulating levels of MMPs 1, 8, 9 and TIMP-1 were negatively associated with high-density lipoprotein cholesterol level. Furthermore, MMP-8 and TIMP-1 were positively related to body mass index and the inflammatory marker CRP. Elevated plasma levels of MMP-7 and TIMP-1 were associated with a higher incidence of hypertension, and MMPs 1 and 7 were similarly increased with incident DM. Individuals who used statins were more likely to have elevated plasma levels of MMPs 1, 2, and 7. No obvious relationships were observed between circulating levels of MMPs and TIMP-1 and smoking status or family history of CVD. However, individuals with a self-history of CVD were more likely to have elevated (tertile 3) MMP-3 plasma levels.
The Supplemental Table ( available online at http://atvb. ahajournals.org) shows the age-adjusted and race-and sexspecific plasma levels of MMPs and TIMP-1. Plasma levels of MMPs 2 and 3 were significantly higher in men than women of either race. In contrast, plasma levels of MMP-7 were lower overall in men than women. Furthermore, blacks had increased plasma levels of MMPs 7, 8, and 9 when compared with whites. Strikingly, circulating levels of MMP-9 were elevated nearly 2-fold in blacks. In addition to circulating levels of MMPs, several traditional cardiovascular risk factors also differed significantly by ethnicity and sex. CRP was increased in women compared with men and was higher overall in blacks than in whites. The prevalence of both hypertension and DM was also higher overall in blacks than in whites.
The simultaneous measurement of several different MMPs in this large cohort study enabled us to investigate potentially significant interrelationships, which are summarized in Table  2 . Generally, correlations between the various MMPs and BMI indicates body mass index (calculated as weight in kilograms divided by height in meters squared); CHD, coronary heart disease; CRP, C-reactive protein; CVD, cardiovascular disease; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MMP, matrix metalloproteinase; TIMP, tissue inhibitor of metalloproteinase.
*For a test of any differences between means. †Data are given as weighted mean (SE) unless otherwise indicated. ‡Data are given as weighted proportion (SE) unless otherwise indicated.
TIMP-1 were low to moderate (Pearson R varied from Ϫ0.008 [between TIMP-1 and MMP-9] to 0.352 [between TIMP-1 and MMP-7]). TIMP-1 showed significant positive correlations with all MMPs measured, with the exception of MMP-9. In contrast, MMP-9 did not correlate with any of the other MMPs measured, except for a significant positive correlation with MMP-8.
The weighted means or proportions of traditional cardiovascular risk factors and MMPs and TIMP-1, adjusted by age, race, and sex, are shown in Table 3 . The results are stratified into high and low IMT groups, based on ultrasonographic examination results for participant selection, as described in the "Study Design and Participants" section. Systolic BP, body mass index, smoking (both current and former), hypertension, and lipid-lowering medication (statin) use were all greater in the high IMT group. Furthermore, circulating levels of MMPs 1, 3, and 7 were significantly elevated in the high IMT participants.
We examined the relationship of individual MMPs and TIMP-1 with various carotid wall measures, as determined by MRI (Table 4 ). Circulating levels of MMP-7 (Pϭ0.04) and TIMP-1 (Pϭ0.02) were positively and statistically significantly associated with total wall volume after adjustment for major cardiovascular risk factors. To examine the possible associations of circulating levels of MMPs and TIMP-1 with plaque burden, we included the derived MRI variable, NWI, in our analysis, as previously described by Saam et al. 16 NWI is calculated as the wall area divided by the total vessel area (ie, wall area plus lumen area). NWI accounts for inherent differences in wall area among vessels of differing diameters and, therefore, may provide a more accurate measure of plaque burden than measurement of stenosis alone. 17 Plasma levels of MMPs 3 and 7 and TIMP-1 were positively associated with NWI after adjustment for major cardiovascular risk factors. To further investigate the relationship of MMPs and TIMP-1 with various carotid MRI variables, we focused our analyses on those participants who had a maximum carotid wall thickness of greater than 1.5 mm and an atherosclerotic plaque, as determined by the presence of a lipid core (Table 5 ). Regression analysis showed that circulating levels of TIMP-1 were independently and positively associated with fibrous cap thickness in a fully adjusted model (Pϭ0.04). Additional analysis, in which fibrous cap thickness was treated as a dichotomized variable (ie, above or below the weighted median), showed that individuals with plasma TIMP-1 levels in the third tertile had an odds ratio of 1.42 (95% CI, 0.79 to 2.55) for increased fibrous cap thickness compared with those individuals with TIMP-1 levels in the first tertile.
Plasma levels of MMPs 1 and 7 were positively associated with carotid artery calcification, although the association for MMP-1 did not quite reach significance at PϽ0.05. Interestingly, MMP-9 showed a moderate inverse association with carotid artery calcification. Both MMP-9 (Pϭ0.006) and TIMP-1 (Pϭ0.01) levels were associated with measures of lipid core, including maximum lipid core area and maximum lipid core volume. However, MMP-9 and TIMP-1 levels were significantly elevated in the second tertile only. Additional analyses showed that circulating levels of TIMP-1 were associated with increased odds for the presence of lipid core in a model adjusted for age, sex, and race, although the odds were somewhat attenuated in a fully adjusted model ( Table 6 ).
Discussion
Plasma levels of MMPs and TIMP-1 were associated with several conventional cardiovascular risk factors (Table 1 ). In particular, we found positive associations with age for most MMPs and TIMP-1, with the exception of MMP-9. In 1 of the few studies designed to investigate the effect of age on MMPs and TIMPs, a small cross-sectional study 18 of 27 asymptomatic individuals aged 20 to 90 years examined the plasma concentrations of MMPs 2, 7, 8, and 9 and TIMPs 1, 2, and 4. The researchers reported increased levels of MMPs 2 and 7 and all TIMPs, and reported no change in MMP-8 levels with age, the latter result being the only deviation from the current finding. Plasma levels of MMP-8 and TIMP-1 were positively associated with body mass index and CRP (the inflammatory marker). Furthermore, hypertensive subjects and diabetic subjects were more likely to have elevated levels of MMPs 1 and 7 and TIMP-1. Overall, our findings show that circulating levels of MMPs and TIMP-1 were associated with an adverse cardiovascular risk profile and, therefore, are supportive of the current belief that MMPs play a critical role in the etiology of atherosclerosis and CVD.
The ARIC Carotid MRI study also provided a unique opportunity to examine the effect of race and sex on plasma levels of MMPs and TIMP-1 in a large biracial population. We found that plasma levels of MMPs 2 and 3 were significantly increased and that the MMP-7 level was decreased in men compared with women ( Supplemental  Table) . A similar finding was observed in a case-control study of 387 patients with myocardial infarction in whom the MMP-3 serum concentrations for both case and control *Data are given as the weighted mean (SE) unless otherwise indicated. Data are adjusted by age, race, sex, smoking status, hypertension, C-reactive protein level, diabetes mellitus, and total and high-density lipoprotein cholesterol levels.
†For a test of any differences between tertiles. *Data are given as the weighted mean (SE) unless otherwise indicated. Data are adjusted by age, race, sex, smoking status, hypertension, C-reactive protein level, diabetes mellitus, and total and high-density lipoprotein cholesterol levels; and are restricted to participants with a maximum wall thickness of greater than 1.5 and a lipid core of 1.
†For a test of any differences between tertiles.
subjects were almost double for men compared with women. 19 Furthermore, in our biracial study cohort, the levels of MMPs 7, 8, and 9 were elevated in blacks compared with whites.
Several studies have shown that the possible pleiotropic effects of statins may involve the down-regulation of MMP expression. Cerivastatin inhibited the secretion of inducible MMPs 1, 3, and 9 from human SMCs. 20 In a study 21 of 32 patients with coronary artery disease, 14 weeks of simvastatin treatment significantly reduced the plasma MMP-9 concentration. Statins may elicit some of their atheroprotective functions by decreasing MMP levels, thus leading to stabilization of the plaques, with or without lesion regression. Our results, which show that MMPs 1 and 2 were negatively associated with low-density lipoprotein cholesterol level and that individuals with elevated plasma levels of MMPs 1 and 2 were more likely to be receiving statin therapy (Table 1) , may appear to contradict the findings from these previous studies. However, our findings may be confounded because high-risk patients (ie, those with coronary heart disease) were more likely to be taking a statin. In addition, the ARIC study was not designed to investigate the possible effects of statin therapy on circulating MMP levels.
We investigated the interrelationships among MMPs and TIMP-1 plasma concentrations ( Table 2 ). Significant correlations may result from coordinated gene expression or could represent a commonality of the tissues and cell types responsible for production of the MMPs that are mutually up-or down-regulated in response to shared agonists or antagonists. 22 We found that levels of MMPs 8 and 9 were correlated with each another (rϭ0.21, PϽ0.001). A significant relationship between MMP-8 and MMP-9 was also found in a study 23 of carotid endarterectomy specimens, and strong correlations between those MMPs were noted in a study 24 of adolescents. MMPs 8 and 9 are both synthesized by differentiating granulocytes, stored in circulating neutrophils, and released after neutrophil activation, 25 a mutuality that could partially explain their association. TIMP-1 was significantly positively correlated with all MMPs, except MMP-9; among these significant correlations, the association with MMP-8 was the weakest. The strongest correlation (rϭ0. 35) was found between TIMP-1 and MMP-7, suggesting that their regulation may be closely linked. In the present study, both MMP-7 and TIMP-1 concentrations were significantly associated with total wall volume, maximum wall thickness at the lipid core, and NWI, suggesting shared functional associations possibly related to their correlation.
Circulating levels of MMPs 1, 3, and 7 were elevated among participants in the high IMT group, as determined by ultrasonographic examination findings (Table 3) . Furthermore, plasma MMP-7 and TIMP-1 levels were associated with increased total wall volume, as determined by MRI, when modeled in tertiles. The NWI was associated with increased levels of MMPs 3 and 7 and TIMP-1. Although NWI is recognized as an indicator of plaque burden, the measurement itself does not directly involve the lipid core or fibrous cap. The elevated plasma levels of MMPs and TIMP-1 associated with measures of increased carotid wall thickness may reflect their increased production, leading to active arterial wall remodeling.
In addition to early atherosclerosis, MMPs have also been associated with plaque progression and the development of the so-called vulnerable plaque. 10, 22 Although there are discordant reports 26, 27 concerning the effect of calcium on plaque stability, arterial calcification has often been associated with plaque vulnerability. Alternatively, arterial calcification may simply reflect overall atherosclerotic burden. In the present study, a significant association was found between plasma MMP-7 level and calcium area, suggesting a possible role for MMP-7 in arterial calcification.
Circulating levels of TIMP-1 were positively associated with the presence of the lipid core and the lipid core area, as measured by MRI. Furthermore, an elevated plasma TIMP-1 level was associated with increased mean fibrous cap thickness. Taken together, our findings suggest that TIMP-1 may be involved in processes leading to thickening of the carotid artery wall and plaque progression into plaques with large lipid cores. However, the positive association of plasma TIMP-1 levels with mean fibrous cap thickness may point to a possible role for TIMP-1 in plaque stabilization. Several in vitro studies and studies in animals and humans have investigated the possible role of TIMP-1 in the etiology of atherosclerosis. However, to our knowledge, there are only limited data available pointing to a possible causal link between TIMP-1 and atherosclerotic plaque progression. TIMP-1 has been shown to have a mitogenic effect on human aortic SMCs, suggesting that it may contribute to SMC proliferation in atherosclerosis. 28 In a prospective study 29 of patients undergoing coronary angiography, an elevated plasma TIMP-1 level was an independent predictor of allcause mortality and myocardial infarction. Furthermore, increased circulating levels of TIMP-1 were associated with the presence of carotid artery lesions in a study 30 of subjects with hyperlipidemia. In contrast, we recently reported that plasma TIMP-1 levels were not predictive of incident coronary artery disease in a case-random cohort sample of the ARIC study. 31 However, it is plausible that differences in study design and population may be partly responsible for these seemingly contradictory findings. Alternatively, the TIMP-1 level could be up-regulated in response to generalized MMP overexpression as a protective mechanism to prevent excessive extracellular matrix degradation and plaque destabilization. 22 In the present study, several factors could explain the many significant associations observed between MMPs and TIMP-1 and variables related to general measures of the carotid wall compared with MRI variables specific to plaque. First, determinations such as wall thickness include the entire study group of 1678, whereas measures of plaque characteristics are limited to only the 569 participants with a detectable lipid core, leading to differences in statistical power. Second, the resolution of the MRI limits the ability to characterize small plaques, restricting the study to the largest plaques found within the thickest arterial walls. Therefore, by truncating the distribution of lipid core volume and cap thickness, possible associations with MMP levels may have gone undetected in our study.
There are several limitations to the current study. First, levels of MMPs and TIMP-1 were measured in the circulation rather than in the arterial wall itself. Although it has been demonstrated that several different cell types present in atherosclerotic lesions are capable of MMP and TIMP synthesis, it is unlikely that circulating MMP levels solely reflect their release from atherosclerotic plaques. Instead, it is more likely that systemic MMP and TIMP levels reflect their general release from the vasculature, as well as interstitial compartments and other nonvascular sources. However, several investigators 11, 12, 32, 33 have reported associations between circulating MMP and TIMP-1 levels and the severity of atherosclerosis.
Second, the levels of total MMPs and TIMP-1 were measured; however, it is the active forms of the MMPs that are responsible for their enzymatic functions. All of the MMPs studied herein are secreted as the proenzyme; therefore, this zymogen form is initially present before activation. If the synthesis and secretion of MMPs and TIMP-1 are increased in response to factors that regulate arterial remodeling events, then an increase in the total forms of the MMPs might be an indicator of increased remodeling activity. It would be most informative to measure the active forms in conjunction with the total forms of these proteases. The additional measurement of the active forms of the MMPs and their association with arterial wall characteristics would be desirable in future studies because such data are lacking.
There are also strengths to the current study. First, the study group was selected from the well-characterized biracial population-based ARIC cohort; to our knowledge, this is the largest population-based study investigating the relationship of several MMPs and TIMP-1 with quantitative measures of carotid wall components using a gadolinium contrastenhanced MRI examination. Second, a standardized MRI protocol with a central reading facility was used; extensive quality control data were collected, allowing assessment of the reliability of the MRI measures and of MMP and TIMP-1 plasma concentrations.
Several investigators 34, 35 have noted the importance of blood collection procedures, especially concerning the measurements of circulating MMPs and TIMP-1. There is great discordance in the literature regarding the effects of MMPs and TIMPs, which could be in part the result of blood collection procedures. Serum levels of several of these analytes are influenced by the release of MMPs and TIMP-1 after the degranulation of leukocytes and platelets during the ex vivo blood clotting process in the specimen collection tube. The extent of this elevation varies for the specific analyte measured, but TIMP-1 and MMPs 1, 8, and 9 have been measured 5 to 20 times higher in serum than in plasma. Because such elevated serum levels result in high background levels, it is generally agreed that plasma, the clinical specimen used in this study, is the preferred source for MMP and TIMP-1 measurement. 34 When comparing data from clinical studies related to circulating concentrations of MMPs, attention should be given to the method of blood collection used.
In summary, our data indicate that circulating levels of MMPs and TIMP-1 are associated with distinct carotid wall characteristics. Additional studies are needed to investigate the relationship between MMPs and atherosclerosis burden.
